Algnomics Joins "Lilly Gateway Labs" in San Diego, US
Promoting RNA Drug Development and Global Commercialization
Algnomics, a company developing RNA-based gene therapies, announced on the 24th that it will join Lilly Gateway Labs, located in San Diego, United States.
Lilly Gateway Labs is a bio-innovation hub that provides bio companies with wet lab facilities as well as opportunities for interaction with Eli Lilly researchers and executives. Together with Lilly Ventures, Lilly Explore R&D, and Lilly TuneLab, it forms part of Lilly’s biotech support program, 'Lilly Catalyze360.'
Through its entry into this facility, Algnomics plans to accelerate the development of therapeutic candidates utilizing its gene bank of over 200 target diseases. Over the long term, the company also aims to establish a global clinical infrastructure for its core pipelines, expand global partnerships, and secure local research talent in the United States.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Sungwook Lee, CEO of Algnomics, stated, “Becoming part of the biotech cluster led by Eli Lilly represents a meaningful milestone for Algnomics’s RNA platform,” and added, “Based on collaboration with the global biotech ecosystem, we will advance the development and commercialization of RNA therapies.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.